Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT02545478
Recruiting Observational

Biomarkers in Infection

NCT02545478 · tracked via the Priya Life Science Israel tracker
Sponsor
Beth Israel Deaconess Medical Center
Phase
Observational
Started
2006-04
Last updated
2026-04-15

Condition(s) studied

SepsisInfectionInflammation

Study summary

The purpose of this investigation is to evaluate how early biomarkers of infection and inflammation perform in identifying patients at risk for poor outcome in sepsis and septic shock.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria for Infected subjects: * Age 18 years of age or older * Confirmed or suspected infection Inclusion Criteria for Control Subjects: * Age 18 years of age or older * A non-infectious clinical presentation to include * Normal white blood cell count ( \> 4,000 and/or \< 12,000) * Normothermia ( \> 96.5 and/or less 100.4) * Absence of the following clinical complaints: productive cough, fever, pyuria, rash * No evidence of acute coronary syndrome Exclusion Criteria for Control Subjects: \- Suspected infection

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Massachusetts General Hospital Boston Massachusetts Active Not Recruiting
Beth Israel Deaconess Medical Center Boston Massachusetts Recruiting

More Beth Israel Deaconess Medical Center trials in Israel

Pain Control for Cervical Ripening Balloon Recruiting
Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana Active, not recruiting
Mechanical Ventilator Adjustments and Patient Dyspnea Starting soon
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model Active, not recruiting
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy Recruiting

Other trials for the same condition

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events Active, not recruiting
Evaluation of Microbial and Endocrinological Parameters in Dialysis Patients With Sepsis Recruiting
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections. Active, not recruiting
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients Recruiting
Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02545478 on ClinicalTrials.gov ↗ ← All trials in Israel